CD38 and renal cell carcinoma: Additionally, among renal cell carcinoma (RCC) patients (n = 36) receiving multiple aPD-1 monotherapy or combination treatments, the greater the increase in HLA-DR+CD38+CD8+ T cells post-treatment, the more significant the reduction in tumor size was observed [104].